Want to see GTBP full AI Analyst Report?
Top Page
GT Biopharma
(NASDAQ:GTBP)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.28
▼(-11.56% Downside)
Action:Upgraded
Date:08/17/26
The score is driven primarily by weak financial performance (no revenue, sizable losses, and accelerating cash burn) and a bearish technical backdrop (price below key moving averages with negative MACD). Valuation metrics provide limited support due to a negative P/E and no dividend data, while recent corporate actions add some structural flexibility but introduce dilution/reverse-split risk.
Positive Factors
Zero Debt
The absence of debt limits interest and refinancing pressure, preserving flexibility for research and clinical development. This is an important structural strength for a pre-revenue biotechnology company, although it does not offset the need for additional operating funding.
Negative Factors
No Commercial Revenue
GT Biopharma remains pre-commercial, so it lacks product revenue to fund operations or validate commercial demand. Continued losses leave financial performance dependent on clinical progress, partnerships, or external capital rather than an established operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero Debt
The absence of debt limits interest and refinancing pressure, preserving flexibility for research and clinical development. This is an important structural strength for a pre-revenue biotechnology company, although it does not offset the need for additional operating funding.
Read all positive factors
GT Biopharma (GTBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.12M
Dividend YieldN/A
Average Volume (3M)1.63M
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS Growth75.09%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.16
Shares Outstanding44,338,573
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.34
Revenue Forecast (FY)N/A
GT Biopharma Business Overview & Revenue Model
Company Description
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tr...
How the Company Makes Money
null...
GT Biopharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -20.38M | -28.23M | -13.16M | 5.98M | -20.96M | -57.48M |
| Net Income | -22.08M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
Balance Sheet | ||||||
| Total Assets | 5.79M | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Cash, Cash Equivalents and Short-Term Investments | 4.96M | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Total Debt | 0.00 | 0.00 | 0.00 | 58.00K | 174.00K | 31.00K |
| Total Liabilities | 2.22M | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Stockholders Equity | 3.57M | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
Cash Flow | ||||||
| Free Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Operating Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investing Cash Flow | 0.00 | 0.00 | 12.89M | -2.01M | 12.14M | -23.04M |
| Financing Cash Flow | 14.16M | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
GT Biopharma Technical Analysis
Negative
0.32
Price Trends
0.39
Negative
0.39
Negative
0.51
Negative
Market Momentum
-0.02
Negative
39.35
Neutral
30.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 0.32 is above the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.39, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.35 is Neutral, neither overbought nor oversold. The STOCH value of 30.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.
GT Biopharma Risk Analysis
GT Biopharma disclosed 60 risk factors in its most recent earnings report. GT Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GT Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.87M | -0.33 | -127.91% | ― | ― | 88.77% | |
46 Neutral | $4.18M | -0.15 | -107.66% | ― | ― | 95.51% | |
44 Neutral | $10.46M | -0.34 | -178.29% | ― | ― | 94.38% | |
43 Neutral | $8.44M | -0.10 | -251.51% | ― | ― | 78.16% | |
41 Neutral | $13.12M | -0.07 | -901.32% | ― | ― | 75.09% |
* Healthcare Sector Average
GTBP
GT Biopharma
0.30
-1.19
-80.07%
TOVX
Theriva Biologics
0.23
-0.21
-48.18%
REVB
Revelation Biosciences
1.05
-9.79
-90.32%
DRMA
Dermata Therapeutics
1.46
-4.46
-75.34%
CERO
CERo Therapeutics Holdings
0.01
-8.79
-99.88%
AZTR
Azitra Inc
0.14
-0.83
-85.60%
GT Biopharma Corporate Events
Business Operations and StrategyShareholder MeetingsStock Split
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan
Positive
Aug 14, 2026
On August 14, 2026, GT Biopharma, Inc. held its Annual Meeting of Stockholders, with approximately 52.68% of eligible shares represented, and shareholders elected four directors and ratified Weinberg Company, P.A. as independent accountants for t...
Business Operations and StrategyShareholder Meetings
GT Biopharma Lowers Stockholder Quorum to One-Third
Positive
Jun 12, 2026
On June 8, 2026, GT Biopharma’s board approved an amendment to its Amended and Restated Bylaws to lower the stockholder quorum requirement at meetings from a majority of outstanding shares entitled to vote to one-third of such shares. This c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.